Imidazoline I2 receptor density increases with the malignancy of human gliomas

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 75, Issue 5, 2004, Pages 785-787

  Callado, L F ^a   Martin Gomez J I ^a   Ruiz, J ^a   Garibi, J M ^b   Meana, J J ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b HOSPITAL DE CRUCES   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

IMIDAZOLINE I2 RECEPTOR;

AFFINITY LABELING; ARTICLE; BRAIN HOMOGENATE; BRAIN TUMOR; CADAVER; CANCER GRADING; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; FEASIBILITY STUDY; GLIOMA; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DENSITY; STATISTICAL SIGNIFICANCE;

BINDING SITES; BRAIN NEOPLASMS; CELL COUNT; FEASIBILITY STUDIES; GLIAL FIBRILLARY ACIDIC PROTEIN; GLIOMA; HUMANS; IDAZOXAN; NEOPLASM STAGING; RECEPTORS, DRUG;

EID: 11144358024     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.2003.020446     Document Type: Article

References (20)

1. Rusell DS, Rubinstein LJ. Pathology of tumours of the nervous system, 5th ed. London: Edward Arnold, 1989.
2. Andratschke N, Grosu AL, Molls M, et al. Perspectives in the treatment of malignant gliomas in adults. Anticancer Res 2001;21:3541-50.
3. Bruner JM, Inouye L, Fuller GN, et al. Diagnostic discrepancies and their clinical impact in a neuropathology referral practice. Cancer 1997;79:796-803.
4. Coons SW, Johnson PC, Scheithauer BW, et al. Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 1997;79:1381-93.
5. Rasheed A, Hemdon JE, Stenzel TT, et al. Molecular markers of prognosis in asfrocytic tumors. Cancer 2002;94:2688-97.
6. Regunathan S, Feinstein DL, Reis DJ. Expression of non-adrenergic imidazoline sites in rat cerebral cortical astrocytes. J Neurosci Res 1993;34:681-8.
7. Olmos G, Alemany R, Escriba PV, et al. The effects of chronic imidazoline drug treatment on glial fibrillary acidic protein concentrations in rat brain, Br J Pharmacol 1994;108:597-603.
8. 2-imidazoline receptors in human glioblastomas. Neuroreport 1996;7:1393-6.
9. 2-imidazoline sites) are increased in postmortem brain from patients with Alzheimer's disease. Neurosci Lett 1993;160:109-12.
10. Munson PJ, Rodbard D. LIGAND: a versatile computerized approach for characterization of ligand binding system. Anal Biochem 1980;107:220-39.
11. Hancock AA, Bus EN, Stanisic D, et al. Data normalization before statistical analysis: keeping the horse before the cart. Trends Pharmacol Sci 1988;9:29-32.
12. 2 with monoamine oxidase-B sites. J Neurochem 1993;61:881-9.
13. Takada A, Mitsuka S, Diksic M, et al. Autoradiographic study of peripheral benzodiazepine receptors in animal brain tumor models and human gliomas. Eur J Pharmacol 1992;228:131-9.
14. Yamada SM, Yamada S, Hayashi Y, et al. Fibroblast growth factor receptor (FGFR) 4 correlated with the malignancy of human astrocytomas. Neurol Res 2002;24:244-8.
15. 1 receptors in progression of human gliomas. Life Sci 2000;67:985-1001.
16. 1 receptor is present in gliomas cells; its blockage reduces the growth of rat gliomas. Br J Cancer 2001;85:1396-9.
17. Rickman DS, Bobek MP, Misek DE, et al. Distinctive molecular profiles af high-grade and low-grade gliomas based on oligonucleotide microarray analysis. Cancer Res 2001;61:6885-91.
18. Watson MA, Perry A, Budhjara V, et al. Gene expression profiling with oligonucleotide microarrays distinguishes World Health Organization grade of oligodendrogliomas. Cancer Res 2001;61:1825-9.
19. Schmidt MC, Antweiler S, Urban N, et al. Impact of genotype and morphology on the prognosis of glioblastoma. J Neuropathol Exp Neurol 2002;61:321-8.
20. Spence AM, Muzi M, Krohn KA. Molecular imaging of regional brain tumor biology. J Cell Biochem 2002;87:25-35.